7 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Mycobacterium tuberculosis ... infection (TB) ... Opportunistic #Infections #OIs ... #management #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Mycobacterium tuberculosis ... infection (TB) ... Opportunistic #Infections #OIs ... #management #pharmacology
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
90%) & develop latent ... Diagnosis: Latent ... staining, NAA (PCR ... #TB #Diagnosis ... #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
90%) & develop latent ... Diagnosis: Latent ... staining, NAA (PCR ... #TB #Diagnosis ... #Management #Treatment
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Multi-Drug Resistant Tuberculosis ... #MDRTB #management ... antimicrobials #regimens #pharmacology ... #dosing #idsa #
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
for active or latent ... and molecular diagnostic ... #TB #IDSA #Prevention ... #Treatment #management ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
IDSA Recommendations ... , Multicentric Castleman ... #IDSA #Prevention ... #Treatment #management ... infections #HIVAIDS #pharmacology